Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite surges for obesity drugmakers Eli Lilly and Novo Nordisk. But the sector is off to a healthy start in 2025.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

In the lawsuit, AG Gentner Drummond outlined 200 individual prescription claims that were reimbursed below acquisition cost to 15 Oklahoma pharmacies.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Pharmacies across Oklahoma say they are losing hundreds of thousands of dollars because they say a company, CVS Caremark, is supposed to reimburse them for prescriptions and isn't holding up their end of the bargain.

Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs. The lawsuit alleges CVS Caremark reimbursed Oklahoma pharmacies below the actual cost to acquire the drugs about 200 times between May and October 2024.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical lawsuits against the biggest insulin makers and against the pharmacy middlemen that decide whether to cover the drugmakers' products.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of